

IntelGenx Technologies Corp.
Form 8-K
October 01, 2014

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

October 1, 2014
Date of Report (Date of Earliest Event Reported)

IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

| | | |
|--|---|--|
| Delaware (State or other jurisdiction of incorporation) | 000-31187 (Commission File Number) | 870638336 (IRS Employer Identification No.) |
|--|---|--|

| | |
|--|-----------------------|
| 6425 Abrams, Ville St- Laurent, Quebec, Canada (Address of principal executive offices) | H4S 1X9 (Zip Code) |
|--|-----------------------|

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
 - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

Item 8.01 Other Events - News Release

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT®

| Exhibit | Description |
|-------------|----------------------|
| <u>99.1</u> | <u>Press Release</u> |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Dated: October 1, 2014

By: /s/ Paul A. Simmons
Paul A. Simmons
Chief Financial Officer
